Location · Oklahoma City, OK
Clinical trials in Oklahoma City, OK
171 recruiting studies have a site in the Oklahoma City area, and 32 of them accept healthy volunteers. The area includes Edmond, Norman, Moore, Midwest City, Yukon and nearby cities.
171 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie
- Location
- Dothan, AL + 53 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Tucson, AZ + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Birmingham, AL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Little Rock, AR + 26 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Janssen Research & Development, LLC
- Location
- Glendale, AZ + 20 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
AstraZeneca
- Location
- La Palma, CA + 14 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC
- Location
- Dothan, AL + 35 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
Biosense Webster, Inc.
- Location
- Birmingham, AL + 10 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
Edwards Lifesciences
- Location
- Los Angeles, CA + 30 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Mesa, AZ + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Gilbert, AZ + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
GlaxoSmithKline
- Location
- Anniston, AL + 93 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
Merck Sharp & Dohme LLC
- Location
- Garden Grove, CA + 12 other US sites
- Eligibility basics
- Ages 18–70
- Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
ReGelTec, Inc.
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 22–85
- RecruitingPhase 3
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
- Location
- Orange, CA + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Novo Nordisk A/S
- Location
- Birmingham, AL + 42 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Glaukos Corporation
- Location
- Grand Junction, CO + 2 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Medtronic Cardiovascular
- Location
- Birmingham, AL + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Pfizer
- Location
- Glendale, AZ + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Corxel Pharmaceuticals
- Location
- Birmingham, AL + 32 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Edwards Lifesciences
- Location
- Irvine, CA + 44 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Fairhope, AL + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 4
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or…
Bristol-Myers Squibb
- Location
- New York, NY + 1 other US site
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
AstraZeneca
- Location
- Foley, AL + 53 other US sites
- Eligibility basics
- Ages 40–80